Francesco Passiglia

Featured in: Favicon

nature.com Favicon

sagepub.com Favicon

thelancet.com Favicon

ejcancer.com Favicon

lungcancerjournal.info Favicon

cancertreatmentreviews.com Favicon

onlinelibrary.wiley.com Favicon

journals.sagepub.com

Articles

Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?

Feb 6, 2023 | thelancet.com | Francesco Passiglia |Silvia Novello

In this issue of eClinicalMedicine, Ou and colleagues published the results of the CORIN (GASTO1003), phase II, randomised trial, comparing adjuvant therapy with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), icotinib, versus clinical observation in 128 patients with surgically resected, EGFR-mutant, stage IB (7th TNM edition) non-small cell lung cancer (NSCLC) without adjuvant chemotherapy. 1Ou W. Li N. Wang B.-X. et al.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →